TSOI Therapeutic Solutions International Inc.

Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer

Therapeutic Solutions International adds Nano Cannabidiol to NanoMyros for Inhibition of Microvesicle and Exosome Release in Prostate Cancer

OCEANSIDE, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Therapeutic Solutions International, Inc. () announced today the addition of nano particle cannabidiol to NanoMyros in the form of its proprietary product Nano Cannabidiol.   

Cannabidiol (also known as CBD), a phytocannabinoid derived from the cannabis species, is devoid of psychoactive activity, but has analgesic, anti-inflammatory, antineoplastic and chemopreventive activities. Upon administration, cannabidiol (CBD) exerts its anti-proliferative, anti-angiogenic and pro-apoptotic activity through various mechanisms.

The addition of "Nano Cannabidiol" to NanoMyros is to inhibit microvesicles and exosomes from being released by other cells in communication intracellularly through the transfer of proteins. Microvesicle and exosome release has been associated with multiple pathologies, including many cancers, which increases drug resistance and the transfer of other pro-oncogenic factors.

"This final piece of this unique synergistic blend of pterostilbene, glucoraphanin, myrosinase, and now cannabidiol is not available by any other manufacturer that we are aware of and is built entirely on our nano products NanoStilbene and Nano Cannabidiol," said Timothy Dixon, President, and CEO of Therapeutic Solutions International. "We will offer the NanoMyros with and without Nano Cannabidiol so as not to restrict anyone from the benefits of NanoPSA and NanoMyros as stand-alone nutraceuticals."



"Preliminary data from our collaborators indicates that this combination is effective at decreasing both production of pathological exosomes, as well as the responsiveness of target cells to pathological exosomes," said Thomas Ichim, Ph.D., Board Member of TSOI.  "Specifically, we have demonstrated that subsequent to treatment of cancer cells using the combination product, there was both a decrease in the production of Fas ligand bearing exosomes, which are known to kill immune cells, as well as an increased resistance of immune cells to killing by Fas ligand bearing exosomes produced by cancer."



About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is and e-commerce at .

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

CONTACT INFORMATION

Therapeutic Solutions International, Inc.

EN
15/07/2019

Underlying

Reports on Therapeutic Solutions International Inc.

 PRESS RELEASE

Therapeutic Solutions International Successfully Treats “No Option” Pa...

OCEANSIDE, Calif.--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI) announced today successful treatment of 15 recent patients under the Right to Try Law with the Company’s universal donor JadiCell™ adult stem cell product. All patients displayed no adverse events and demonstrated subjective and objective levels of improvement. There were 12 COVID-19 patients who underwent a profound recovery despite advanced stage of disease, while the retired Navy SEAL that was previously publicly disclosed1 along with two other retired SEALS, had a significant decrease in biomarkers associated ...

 PRESS RELEASE

Therapeutic Solutions International Reports NanoStilbeneâ„¢ Protects t...

Therapeutic Solutions International Reports NanoStilbene™ Protects the Immune System from Cancer Chemotherapy Newly Discovered Properties of NanoStilbene Potentially Allows Company to Address $3.9 Billion Chemotherapy Induced Neutropenia Market OCEANSIDE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Therapeutics Solutions International, Inc., () announced today new data and the filing of a patent application covering the ability of NanoStilbene™ [1] and its active ingredient, pterostilbene, at accelerating recovery of blood cells after treatment with chemotherapy.  Neutropenia is an...

 PRESS RELEASE

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chie...

Feng Lin, MD, Ph.D., Joins Therapeutic Solutions International as Chief Scientific Officer Immuno-Oncology Nutraceutical Company Positions Itself for Expansion into FDA OCEANSIDE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., () announced today the recruitment of Feng Lin, MD, Ph.D., as Chief Scientific Officer.  Dr. Lin has a stellar track record of drug development in the area of immunology and immuno-oncology having worked with the public company Inovio Pharmaceuticals, where he developed technologies for gene delivery an...

 PRESS RELEASE

Therapeutic Solutions International Inc. Reports Revenues Up 850% for ...

Therapeutic Solutions International Inc. Reports Revenues Up 850% for Q2 OCEANSIDE, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- via NetworkWire - Therapeutics Solutions International Inc. (OTC: TSOI) today reports that its second-quarter 2019 revenues increased 850%, as compared to the same period in 2018.  These increases were due primarily to the commercialization of NanoStilbene™ following the completion of clinical program that included a pharmacokinetic trial and a pilot cancer study in advanced cancer patients using 300mg of nanoparticle pterostilbene. As , results of this clinical...

 PRESS RELEASE

Therapeutic Solutions International Announces Positive Clinical Data U...

Therapeutic Solutions International Announces Positive Clinical Data Using NanoStilbene™ to Stimulate Immune System in Advanced Cancer Patients Company Submits Results of Clinical Trial for Publication in Peer Reviewed Medical Journal OCEANSIDE, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Therapeutics Solutions International, Inc., () announced today positive results from a pilot clinical trial in advanced cancer patients which have been submitted as a scientific manuscript to a peer reviewed medical journal.  In the manuscript, 12 advanced cancer patients were treated...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch